The biopharma company is evaluating its experimental immunotherapy against HPV-positive cancers alone and in combination with a bifunctional fusion protein.
The promising response rates seen in the SUMMIT trial may provide further reason to broadly test all advanced cervical cancer patients for precision medicine biomarkers.
The diagnostic can now be used to identify a wider range of patients with stage III or metastatic NSCLC who may benefit from first-line treatment with Keytruda.
Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify urothelial carcinoma patients who may benefit from the anti-PD1 immunotherapy.
